PMI urges FDA to prioritise review of Iqos Iluma modified risk tobacco products

Philip Morris International (PMI) has submitted premarket tobacco product applications (PMTAs) and modified risk tobacco product applications (MRTPAs) to the US Food and Drug Administration (FDA) for its Iqos Iluma heated tobacco products (HTPs).

As previously announced during the presentation of its financial results last week, the company was expected to file the applications by the end of October.

They are strong applications backed by international evidence of how Iqos Iluma products can lead more adults to stop smoking, said Stacey Kennedy, president of Americas Region and CEO of PMI US. She urged the FDA to prioritise them for review.

Read full article
I'm already a subscriber

Antonia Di Lorenzo

Assistant news editor/senior reporter
Antonia is a member of the editorial team and holds a masters degree in Law from the University of Naples Federico II, Italy. She moved in 2013 to London, where she completed a postgraduate course at the London School of Journalism. In the UK, she worked as a news reporter for a financial newswire and a magazine before moving to Barcelona in 2019.

Our Key Benefits

The global novel nicotine market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

TobaccoIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organisation